The DoHAICs Study Expansion Phase

NCT07584018 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

90

Enrollment

OTHER

Sponsor class

Conditions

HCC - Hepatocellular Carcinoma

Interventions

DRUG: Donafenib
DRUG: sintilimab
PROCEDURE: HAIC

Sponsor

Tianjin Medical University Cancer Institute and Hospital